Multidrug resistance in oncology: Diagnostic and therapeutic approaches

European Journal of Clinical Investigation

Volumn 29, Issue 6, 1999, Pages 536-545

  Robert, J ^a  

^a INSTITUT BERGONIÉ   (France)

Author keywords

Cancer chemotherapy; Gene multidrug resistance; MDR1; P glycoprotein

Indexed keywords

ANTINEOPLASTIC AGENT; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN;

ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; GENE EXPRESSION; MULTIDRUG RESISTANCE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0033006305     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.1999.00495.x     Document Type: Article

References (95)

1. 1 Biedler JL, Riehm H. Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross resistance, radioautographic and cytogenetic studies. Cancer Res 1970;30:1174-84.
2. 2 Danø K. Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. Biochim Biophys Acta 1973;323:466-83.
3. 3 Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1978;455:152-62.
4. 4 Kartner N, Riordan JR, Ling V. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Sci 1983;221:1285-9.
5. 5 Kartner N, Evernden-Porelle D, Bradley G, Ling V. Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature 1985;316:820-3.
6. 6 Roninson IB, Avelson HT, Housman DE, Howell N, Varshavsky A. Amplification of specific DNA sequences correlates with multidrug resistance in Chinese hamster cells. Nature 1984;309:606-28.
7. 7 Gerlach JH, Endicott JA, Juranka PF, et al. Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistance. Nature 1986;324:485-9.
8. 8 Gros P, Croop J, Housman D. Mammalian multidrug resistance gene: complete cDNA sequence indicates strong homology to bacterial transport proteins. Cell 1986;47:371 80.
9. 9 Endicott JA, Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 1989;58:137-71.
10. 10 Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993;62:385-427.
11. 11 Ueda K, Cardarelli C, Gottesman MM, Pastan I. Expression of a full-length cDNA for the human MDR1 gene confers resistance to colchicine, doxorubicin and vinblastine. Proc Natl Acad Sci USA 1987;84:3004-38.
12. 12 Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham M. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987;84:7735-8.
13. 13 Cordon-Cardo C, O'Brien JP, Casals D, et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 1989;86:695-8.
14. 14 Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981;41:1967-72.
15. 15 Ford JM, Hait WN. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 1990;2: 155-99.
16. 16 Safa AR. Photoaffinity labeling of P-glycoprotein in multidrug-resistant cells. Cancer Invest 1992;10:295-305.
17. 17 Scala S, Akhmed N, Rao US, et al. P-glycoprotein substrates and antagonists cluster in two distinct groups. Mol Pharmacol 1997;51:1024-33.
18. 18 Ayesh S, Shao YM, Stein WD. Co-operative, competitive and non -competitive interactions between modulators of P-glycoprotein. Biochim Biophys Acta 1996;1316:8-18.
19. 19 Georges E, Sharom FJ, Ling V. Multidrug resistance and chemosensitization. Therapeutic implication for cancer chemotherapy. Adv Pharmacol 1990;21:185-220.
20. 20 Goldstein LJ, Galski H, Fojo A, et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989;81:116-24.
21. 21 Moscow JA, Fairchild CR, Madden MJ, et al. Expression of anionic glutathione S-transferase and P-glycoprotein genes in human tissues and tumors. Cancer Res 1989;49:1422-8.
22. 22 Noonan KE, Beck C, Holzmayer TA, et al. Quantitative analysis of MDR1 multidrug resistance gene expression in human tumors by polymerase chain reaction. Prof Natl Acad Sci USA 1990;87:7160-4.
23. 23 Futscher BW, Blake LL, Gerlach JH, Grogan TM, Dalton WS. Quantitative polymerase chain reaction analysis of MDR1 messenger RNA in multiple myeloma cell lines and clinical specimens. Anal Biochem 1993;213:414-21.
24. 24 Lyttelton MPA, Hart S, Ganeshaguru K, Hoffbrand AV, Mehta AB. Quantitation of multidrug resistant MDR1 transcript in acute myeloid leukaemia by non-isotopic quantitative cDNA-polymerase chain reaction. Br J Haematol 1994;86:540-6.
25. 25 Debuire B, Sol O, Lemoine A, May E. Non-isotopic competitive RT-PCR assay to measure MDR1 gene expression. Clin Chem 1995;41:819-25.
26. 26 Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and cross-reactivity of one antibody with a muscle protein. J Histochem Cytochem 1989;37:159-64.
27. 27 Scheper RJ, Bulte JWM, Brakkee JGP, et al. Monoclonal antibody JSB-1 detects a highly conserved epitope on the P-glycoprotein associated with multidrug resistance. Int J Cancer 1988;42:389-94.
28. 28 Hamada H, Tsuruo T. Functional role for the 170-to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies. Proc Natl Acad Sci USA 1986;83:7785-9.
29. 29 Arceci RJ, Stieglitz K, Bra SJ, Schinkel A, Baas F, Croop J. Monoclonal antibody to an external epitope of the human MDR1 P-glycoprotein. Cancer Res 1993;53:310-7.
30. 30 Mechetner EB, Roninson IB. Efficient inhibition of P-glycoprotein-mediated multidrug resistant with a monoclonal antibody. Proc Natl Acad Sci USA 1992;89: 5824-8.
31. 31 Vergier B, Cany L, Bonnet F, Robert J, de Mascarel A, Coindre JM. Expression of MDR1/P glycoprotein in human sarcomas. Br J Cancer 1993;68:1221-6.
32. 32 Brophy NA, Marie JP, Rojas VA, et al. MDR1 gene expression in childhood acute lymphoblastic leukemias and lymphomas. A critical evaluation by four techniques. Leukemia 1994;8:327-35.
33. 33 Herzog C, Trepel J, Mickley L, Bates SE, Fojo AT. Various methods of analysis of MDR1/P-glycoprotein in human colon cancer cell lines. J Natl Cancer Inst 1992;84:711-6.
34. 34 Zhou DC, Marie JP, Suberville AM, Zittoun R. Relevance of MDR1 gene expression in acute myeloid leukemia and comparison of different diagnostic methods. Leukemia 1992;6:879-85.
35. 35 Beck WT, Grogan TM, Willman CL, et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res 1996;56:3010-20.
36. 36 Broxterman HJ, Sonneveld P, Feller N, et al. Quality control of multidrug resistance assays in adult acute leukemia: correlation between assays for P-glycoprotein expression and activity. Blood 1996;87:4809-16.
37. 37 Marie JP, Huet S, Faussat AM, et al. Multicentric evaluation of the MDR phenotype in leukemia. Leukemia 1997;11:1086-94.
38. 38 Chevillard S, Vielh P, Validire P, et al. French multicentric evaluation of MDR1 gene expression in leukemia and solid tumours. Standardization of RT-PCR and preliminary comparisons between RT-PCR and immunohistochemistry in solid tumours. Leukemia 1997;11:1095-106.
39. 39 Holmes JA, West RR. The effect of MDR1 gene expression on outcome in acute myeloblastic leukaemia. Br J Cancer 1994;69:382-4.
40. 40 Trock BJ, Leonessa F, Clarke R. Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst 1997;89:917-31.
41. 41 Chevillard S, Pouillart P, Beldjord G, et al. Sequential assessment of multidrug resistant phenotype and measurement of the S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy. Cancer 1996;77;292-300.
42. 42 Liu BL, Sun DT, Xia WY, Hung MC, Yu DH. Crossrectivity of C-219 anti-P170 (MDR1) antibody with P185 (c-erbB2) in breast cancer cells: caution on evaluating P170 (MDR1). J Natl Cancer Inst 1997;89:1524-9.
43. 43 Salmon SE, Dalton WS, Grogan TM, et al. Multidrug-resistant myeloma. Laboratory and clinical effects of verapamil as a chemosensitizer. Blood 1991;78:44-50.
44. 44 Mross K. Multidrug resistance modulation in metastatic breast cancer patients. J Clin Oncol 1995;13:303-4.
45. 45 Fischer GA, Lum BL, Hausdorff J, Sikic B. Pharmacological considerations in the modulation of multidrug resistance. Eur J Cancer 1996;32:1082-8.
46. 46 Ozols RF, Cunnion RE, Klecker RW, et al. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol 1987;5:641-7.
47. 47 Durie BGM, Dalton WS. Reversal of drug-resistance in multiple myeloma with verapamil. Br J Haematol 1988;68:203-6.
48. 48 Dalton WS, Grogan TM, Meltzer PS, Scheper RJ, Salmon SE. Drug resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 1989;7:415-24.
49. 49 Salmon SE, Dalton WS, Grogan TM, et al. Multidrug-resistant myeloma. Laboratory and clinical effects of verapamil as a chemosensitizer. Blood 1991;78:44-50.
50. 50 Miller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ, Salmon SE. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 1991;9:17-24.
51. 51 Dalton WS, Crowley JJ, Fojo A, et al. A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma: a Southwest Oncology Group study. Cancer 1995;75:815-20.
52. 52 Demicheli R, Jirillo A, Bonciarelli G, Lonardi F, Balli M, Bandello A. 4′-epidoxorubicin plus verapamil in anthracycline-refractory cancer patients. Tumori 1989;75:245-7.
53. 53 Langenbuch T, Mross K, Jonat W, Hassfeld DK. A phase II study of intensive-dose epirubicin/verapamil as induction therapy followed by intensive-dose ifosfamide for advanced breast cancer. Cancer Chemother Pharmacol 1990;26:93-6.
54. 54 Mross K, Bohn C, Edler L, et al. Randomized phase II study of single agent epirubicin +/-verapamil in patients with advanced metastatic breast cancer. Ann Oncol 1993;4:45-50.
55. 55 Millward MJ, Cantwell BMJ, Munroe NC, Robinson A, Corris PA, Harris AL. Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study. Br J Cancer 1993;67:1031-5.
56. 56 Cairo MS, Siegel S, Sender L. Clinical trial of continuous infusion verapamil, bolus vinblastine, and continuous infusion VP-16 in drug-resistant pediatric tumors. Cancer Res 1989;49:1063-6.
57. 57 Bissett D, Kerr DJ, Cassidy J, et al. Phase I and pharmacokinetic study of D-verapamil and doxorubicin. Br J Cancer 1991;64:1168-71.
58. 58 Scheithauer W, Kornek G, Kastner J, et al. Phase II study of D-verapamil and doxorubicin in patients with metastatic colorectal cancer. Eur J Cancer 1993;29a:2337-8.
59. 59 Motzer RJ, Lyn P, Fischer P, et al. Phase I/II of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma. J Clin Oncol 1995;13:1958-65.
60. 60 Wilson WH, Bates SE, Fojo A, et al. Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. J Clin Oncol 1995;13:1995-2004.
61. 61 Lehnert M, Mross K, Schueller J, Thuerlimann B, Kroeger N, Kupper H. Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer. Br J Cancer 1998;77:1155-63.
62. 62 Sonneveld P, Durie BGM, Lockhorst HM, et al. Modulation of multidrug resistant multiple myeloma by cyclosporin. Lancet 1992;340:255-9.
63. 63 List AF, Spier C, Greer J, et al. Phase I/II trial of cyclosporin A as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 1993;11:24-1634.
64. 64 Verweij J, Herweijer H, Oosterom R, et al. A phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporin A in an attempt to reverse multidrug resistance. Br J Cancer 1991;64:361-4.
65. 65 Rodenburg CJ, Nooter K, Herweijer H, et al. Phase II study combining vinblastine and cyclosporin A to circumvent multidrug resistance in renal cell cancer. Ann Oncol 1991;2:305-6.
66. 66 Sarris AH, Younes A, McLaughlin P, et al. Cyclosporin A does not reverse clinical resistance to paclitaxel in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1996;14:233-9.
67. 67 Twentyman PR, Bleehen NM, Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin. Eur J Cancer 1991;27a:1639-42.
68. 68 Boote DJ, Dennis IF, Twentyman PR, et al. Phase I study of etoposide with SDZ PSC-833 as a modulator of multidrug resistance in patients with cancer. J Clin Oncol 1996;14:610-8.
69. 69 Giaccone G, Linn SC, Welink J, et al. A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC-833 in combination with doxorubicin in patients with solid tumors. Clin Cancer Res 1997;3:2005-15.
70. 70 Lee E, George S, Caligiuri M, et al. A phase I study of induction chemotherapy for older patients with acute myeloid leukemia using ara-C, daunorubicin and etoposide with and without the MDR modulator PSC-833 (Abstract no. 2256). Blood 1997;90 (Suppl. 1):506a.
71. 71 Sonneveld P, Marie JP, Huisman C, et al. Reversal of multidrug resistance by SDZ PSC-833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma. A phase I study. Leukemia 1996;10: 1741-50.
72. 72 Advani R, Saba HI, Tallman M, et al. Treatment of poor prognosis AML with PSC-833 plus mitoxantrone, etoposide, cytarabine (Abstract no. 2260). Blood 1997;90 (Suppl. 1);507a.
73. 73 Kornblau SM, Estey E, Madden T, et al. Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia. J Clin Oncol 1997;15:1796-802.
74. 74 Visani G, Milligan D, Leoni F, et al. A phase I dose-finding study of PSC-833, a novel MDR-reversing agent, with mitoxantrone, etoposide and cytarabine in poor prognosis acute leukemia (Abstract, no. 2518). Blood 1997;90 (Suppl. 1):566a.
75. 75 Sonneveld P, Lowenberg B, Vossebeld P, et al. Dose-finding study of PSC-83, a novel MDR-reversing agent, with daunorubicin and ara-C, in untreated elderly patients with acute myeloid leukemia (Abstract no. 2517). Blood 1997;90 (Suppl. 1):566a.
76. 76 Fields A, Hochster H, Runowicz C, et al. SDZPSC-833 / paclitaxel in paclitaxel-refractory ovarian carcinoma: a phase I trial with renewed responses. Proc Am Soc Clin Oncol 1997;16:351a (Abstract no. 1254).
77. 77 Lush RM, Meadows B, Fojo AT, et al. Initial pharmacokinetics and bioavailability of PSC-833, a P-glycoprotein antagonist. J Clin Pharmacol 1997;37:3-128.
78. 78 Wishart CC, Bissett D, Paul J, et al. Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial. J Clin Oncol 1994;12:1271-7.
79. 79 Solary E, Caillot D, Chauffert B, et al. Feasibility of using quinine, a potential multidrug resistance reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia. J Clin Oncol 1992;10:1730-6.
80. 80 Solary E, Witz B, Caillot D, et al. Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study. Blood 1996;88:1198-205.
81. 81 Miller TP, Chase EM, Dorr R, Dalton WS, Lam KS, Salmon SE. A phase I/II trial of paclitaxel for non-Hodgkin's lymphoma followed by paclitaxel plus quinine in drug-resistant disease. Anticancer Drugs 1998;9:135-40.
82. 82 Genne P, Dimanche-Boitrel MT, Mauvernay RY, et al. Cinchonine, a potent efflux inhibitor to circumvent anthracycline resistance In Vivo. Cancer Res 1992;52:2797-801.
83. 83 Genne P, Caillot D, Casasnovas RO, et al. MDR reversing activity of serum from patients treated with cinchonine (Abstract no. 3987). Proc Am Assoc Cancer Res 1997;38:593-4.
84. 84 Trump DL, Smith DC, Ellis PG, et al. High-dose oral tamoxifen, a potential multidrug-resistance reversal agent. Phase I trial in combination with vinblastine. J Natl Cancer Inst 1992;84:1811-6.
85. 85 Smith DC, Trump DL. A phase I trial of high-dose oral tamoxifen and CHOPE. Cancer Chemother Pharmacol 1995;36:65-8.
86. 86 Millward MJ, Cantwell BM, Lien EA, Carmichael J, Harris AL. Intermittent high-dose tamoxifen as a potential modifier of multidrug resistance. Eur J Cancer 1992;28a:805-10.
87. 87 Pierré A, Dunn TA, Kraus-Berthier L, et al. In vitro and in vivo circumvention of multidrug resistance by Servier-9788, a novel triazinoaminopiperidine derivative. Invest New Drugs 1992;10:137-48.
88. 88 Punt CJA, Voest EE, Tueni E, et al. Phase IB study of doxorubicin in combination with the multidrug resistance reversing agent S-9788 in advanced colorectal and renal cell cancer. Br J Cancer 1997;76:1376-81.
89. 89 Germann U, Shlyakhter D, Mason VS, et al. Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance. In Vitro Anticancer Drugs 1997;8:125-40.
90. 90 Peck RA, Marshall J, Ziessman H, et al. A phase I trial of doxorubicin and VX-710 (Abstract no. 1134). Proc Am Assoc Cancer Res 1996;37:165.
91. 91 Smith L, Rowinsky E, Chaturvedi P, et al. Pharmacokinetic and toxicologic interactions between the multidrug resistance reversal agent VX-710 and paclitaxel in cancer patients (Abstract no. 764). Proc Am Soc Clin Oncol 1997;16:218a.
92. 92 Hyafil F, Vergely C, Duvignaud P, Grandperret T. In vitro and in vivo reversal of multidrug resistance by GF-120918, an acridone carboxamide derivative. Cancer Res 1993;53:4595-602.
93. 93 Mickisch GH, Merlino GT, Galski H, Gottesman MM, Pastan I. Transgenic mice that express the human multidrug resistance gene in bone marrow enable a rapid identification of agents that reverse drug resistance. Proc Natl Acad Sci USA 1991;88:547-51.
94. 94 Mechetner EB, Roninson IB. Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody. Proc Natl Acad Sci USA 1992;89:5824-8.
95. 95 Alahari SK, Dean NM, Fischer MH, et al. Inhibition of expression of the multidrug resistance-associated P-glycoprotein by phosphorothiate and 5' cholesterol-conjugated phosphorothiate antisense oligonucleotides. Mol Pharmacol 1996;50:808-19.